Oviva Diabetes Support: Evaluating clinical outcomes for people with type 2 diabetes following completion of a remote programme of structured education and behaviour change

点击翻译按钮获取中文摘要

"Oviva Diabetes Support is a patient-centred, digitally enabled programme of structured education and behaviour change for people with type 2 diabetes. Delivered 1-to-1 by dietitians, the programme provides individualised care over 10-12 weeks to support completion of a defined curriculum and help the participant learn to manage their condition.It is highly accessible as it is fully remote (delivered via phone calls and the Oviva smartphone app) and the curriculum is delivered via a web-based Oviva Learning Platform, comprised of engaging, multi-format content, such as videos, podcasts and recipes. Participants can also use the Oviva app for self-monitoring of food intake, activity levels and weight, in addition to coaching from their personal dietitian.Building on evidence of effective and accessible approaches to structured education provision, Oviva Diabetes Support aims to equip participants with self-management skills and help them adopt long-term healthier habits through guided behaviour change and self-directed learning.Oviva Diabetes Support has been made available to participants in the NHS in 13 areas and has demonstrated uptake of c.90%, in comparison with the national average of 7.6%, indicating that the innovative service model is far more accessible for users than traditional models.Real-world data also indicates that improvements in health and clinical outcomes for participants are superior and are achieved at lower cost to traditional models.This project will enable 300 participants to access Oviva Diabetes Support. An independent evaluation of the programme's impact on clinical outcomes following completion of the programme will be carried out by King's College London, which will be used to further analyse the potential for NHS cost-savings. In addition, the findings of the evaluation will be used to inform a larger clinical trial in future, which will seek to provide further evidence of clinical effectiveness."